Azithromycin Treatment for Non-eosinophilic Chest Tightness Variant Asthma
Status:
Not yet recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
Bronchial asthma (abbr. asthma) is one of common airway chronic inflammatory disease which
usually threatens human health. Typical symptoms of asthma are recurrent wheezing, shortness
of breath, chest tightness and cough, usually happened at night or in early morning. However,
there are still some patients who persist only clinical manifestations of chest tightness,
namely, chest tightness variant asthma (CTVA). This subgroup of asthma usually lacks
asthma-specific clinical features, therefore, often misdiagnosed and lack of effective
treatment for a long time. Our previous studies have found that CTVA has eosinophilic and
non-eosinophilic subtypes. These patients with non-eosinophilic CTVA (NE-CTVA) are not
sensitive to ICS/LABA, which guidelines recommend. At present, the specific treatment plan
for NE-CTVA is urgently needed to elucidate. Azithromycin has immunomodulatory and
anti-inflammatory effects in addition to their antibacterial effects. Maintenance treatment
with azithromycin has been proved to be effective in chronic neutrophilic airway diseases and
severe asthma. However, there are no clinical studies to confirm the effectiveness of
azithromycin in non-eosinophilic asthma, especially atypical asthma such as NE-CTVA. Now we
performed a national multi-center placebo-controlled study to explore whether azithromycin
improves asthma symptom control and improves quality of life in people with NE-CTVA. Finally,
to find an optimal treatment for NE-CTVA.
Phase:
Phase 4
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University